Journal
KIDNEY INTERNATIONAL
Volume 75, Issue 9, Pages 890-897Publisher
ELSEVIER SCIENCE INC
DOI: 10.1038/ki.2008.644
Keywords
cardiovascular disease; end stage renal disease; hyperphosphatemia; phosphate transport; smooth muscle cells; vascular calcification
Categories
Funding
- NIH [HL18645, HL081785, HL62329]
- Abbott
Ask authors/readers for more resources
Vascular calcification is recognized as a major contributor to cardiovascular disease (CVD) in end stage renal disease (ESRD) patients. Susceptibility to vascular calcification is genetically determined and actively regulated by diverse inducers and inhibitors. One of these inducers, hyperphosphatemia, promotes vascular calcification and is a nontraditional risk factor for CVD mortality in ESRD patients. Vascular smooth muscle cells (SMCs) respond to elevated phosphate levels by undergoing an osteochondrogenic phenotype change and mineralizing their extracellular matrix through a mechanism requiring sodium-dependent phosphate cotransporters. Disease states and cytokines can increase expression of sodium-dependent phosphate cotransporters in SMCs, thereby increasing susceptibility to calcification even at phosphate concentrations that are in the normal range.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available